Waters (NYSE:WAT) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Waters (NYSE:WAT) from a hold rating to a buy rating in a research note released on Monday morning, ValuEngine reports.

Several other equities analysts also recently issued reports on WAT. Citigroup started coverage on Waters in a research report on Monday, January 6th. They issued a sell rating and a $190.00 target price on the stock. Zacks Investment Research downgraded Waters from a hold rating to a sell rating and set a $231.00 target price on the stock. in a research report on Friday, February 7th. TheStreet downgraded Waters from a b rating to a c+ rating in a research report on Tuesday, October 29th. Bank of America raised Waters from an underperform rating to a neutral rating in a research report on Friday, January 3rd. Finally, BTIG Research downgraded Waters from a buy rating to a neutral rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Waters currently has a consensus rating of Hold and a consensus price target of $207.13.

Shares of WAT stock opened at $220.58 on Monday. The business’s fifty day simple moving average is $230.67 and its 200-day simple moving average is $221.41. The company has a market cap of $14.12 billion, a PE ratio of 25.12, a PEG ratio of 2.76 and a beta of 1.10. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 11.40. Waters has a 12-month low of $199.11 and a 12-month high of $255.21.

Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $3.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.01 by $0.19. Waters had a return on equity of 172.16% and a net margin of 24.61%. The business had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.34 million. During the same period in the prior year, the firm posted $2.87 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. On average, equities analysts forecast that Waters will post 9.37 earnings per share for the current year.

In other Waters news, Director Edward Conard sold 1,112 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $221.97, for a total transaction of $246,830.64. Following the sale, the director now directly owns 68,510 shares of the company’s stock, valued at approximately $15,207,164.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joann A. Reed sold 5,194 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $234.67, for a total value of $1,218,875.98. Following the sale, the director now directly owns 25,323 shares in the company, valued at $5,942,548.41. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,794 shares of company stock worth $2,893,456. 1.14% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in WAT. First Trust Advisors LP acquired a new stake in Waters during the 1st quarter worth about $1,744,000. Macquarie Group Ltd. grew its position in Waters by 23.8% during the 2nd quarter. Macquarie Group Ltd. now owns 2,600 shares of the medical instruments supplier’s stock worth $560,000 after purchasing an additional 500 shares during the period. Pacer Advisors Inc. grew its position in Waters by 6.1% during the 3rd quarter. Pacer Advisors Inc. now owns 8,452 shares of the medical instruments supplier’s stock worth $1,887,000 after purchasing an additional 483 shares during the period. Fox Run Management L.L.C. acquired a new stake in Waters during the 3rd quarter worth about $241,000. Finally, Bristol John W & Co. Inc. NY grew its position in Waters by 0.8% during the 3rd quarter. Bristol John W & Co. Inc. NY now owns 275,101 shares of the medical instruments supplier’s stock worth $61,411,000 after purchasing an additional 2,061 shares during the period. 96.66% of the stock is currently owned by institutional investors.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Recommended Story: P/E Growth (PEG)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.